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Introduction
The Epstein-Barr virus (EBV), a double-stranded
DNA virus, a member of Herpesviridae family, sub-
family of Gammaherpesvirinae [1], is associated with
the development of both lymphoid and epithelial
tumours. The principal target cells for EBV infection
involve primary B lymphocytes but the virus can infect
also T lymphocytes and epithelial cells [2-6]. The
infection of human B lymphocytes in vitro results in
immortalisation of the cells and augmented membra-
nous expression of numerous B-cell activation mole-
cules, including CD23, CD30, CD39, CD40, CD44,
and cellular adhesion molecules such as ICAM-1,
LFA-1, and LFA-3 [7,8]. EBV infects B lymphocytes
binding to the type 2 complement receptor (CR2,
CD21), which is followed by internalisation of the
virus [9]. The three-dimensional structure of CD21
fragment (CD21 SCR1-SCR2) has been recognised,
which most probably is responsible for binding of
EBV [10]. In cellular penetration of EBV surface
HLA class II molecules also take part [11]. Following
viral internalisation, DNA of the virus forms an epi-
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Abstract: Epstein Barr virus (EBV) infection of human B lymphocytes in vitro results in immortalisation of the cells and
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Key words: B-cell non-Hodgkin's lymphoma - EBV tissue markers - CD21 and CD23 - Immunocytochemistry - Hybridiza-
tion in situ - ImmunoMax technique - PCR
Correspondence: A. Kasprzak, Dept. Histology and 
Embryology, University of Medical Sciences, Œwiêcickiego 6, 
60-781 Poznañ, Poland; tel.: (+4861) 8546441, 
fax.: (+4861)  8545440, e-mail: akasprza@amp.edu.pl
somal form in cell nuclei of the host and the latent
form of the infection becomes stabilised [7]. At pres-
ent, four patterns of EBV latency are recognised
[12,13]. In the strict type I latency, represented mainly
by Burkitt lymphoma (BL) cells, viral gene expression
is restricted to the two EBER genes, the BART gene,
and the EBNA1 (EBV nuclear antigen 1) gene [13]. In
latency II additional expression of three latent-mem-
brane proteins, LMP-1, LMP-2A and LMP-2B is
observed. It is encountered most frequently in
Hodgkin's lymphoma. Latency III is seen in lympho-
proliferative diseases arising in immunocompromised
individuals and EBV-transformed lymphoblastoid cell
lines. In this group all six EBNAs, all three LMPs and
the two EBERs are expressed [12,13]. Type IV latency
is less strictly defined and pertains infectious mononu-
cleosis patients and patients with a post-transplant
lymphoproliferative disease [13]. Some patients distin-
guish also the so called putative latency program
(latency 0), in which no latent gene undergoes expres-
sion [12]. 
Principal mediators of EBV-induced growth and
cellular transformation of B lymphocytes in vitro
include EBNA2 and LMP1 proteins [7]. EBNA2 is
indispensable for transformation of primary B lym-
phocytes, leading to transactivation of other cellular
and viral genes [2,14]. The protein augments expres-
sion of genes coding CD21, CD23, LMP1 and LMP2
proteins in B lymphocytes [2,7,8]. In the mouse model
LMP1 was found to be critical but not mandatory for the
generation of proliferating B cells in vitro [15]. BZLF1
(ZEBRA) is a DNA-binding protein, which expression
precedes the switch from latent to lytic infection [2].
BZLF1 is a viral transactivator protein triggering
expression of lytic genes and downregulation of latent
genes, culminating in cell death and release of infec-
tious virions. This protein also up-regulates expression
of other immediate early genes as well as expression of
ZEBRA itself. These genes, in turn, up-regulate the
expression of early gene products (viral DNA poly-
merase and thymidine kinase) [2,16]. Two small RNAs
(EBER-1 and EBER-2) represent the most vast types of
EBV RNA in the latent infection and undergo continu-
ous expression in EBV-positive tumours, independently
of their pattern of latency [2,7,12].
Studies performed in vitro demonstrated that CD21
plays role of an EBV receptor and only those B lym-
phocytes which carry the surface CD21 become trans-
formation-competent [2,9,17]. A more pronounced
expression has been noted in more differentiated cell
lines originating from B lymphocytes [18]. Lower
amounts of CD21 were detected on cells of naso-pha-
ryngeal epithelium, immature T lymphocytes and cul-
tures of the cells [3,19-21].
In order to clarify role of Epstein-Barr virus (EBV)
in oncogenesis of B-cell non-Hodgkin's lymphomas in
children a comparative analysis was performed involv-
ing expression of three viral proteins, EBV RNA
(EBER), EBV DNA as well as their correlations with
CD21 and CD23 expression in lymphoid organs. Due
to the potential role of EBV in development of B-cell
NHLs, also in nonendemic areas, we have decided to
characterise the patterns of EBV latency in children in
our country.
Material and methods
Tissue material. Archival paraffin blocks with surgical material
(lymph nodes and extra-nodular neoplastic lesions) originated
from 26 children with B-cell non-Hodgkin's lymphomas of 1 to 16
years of age (mean age: 8±4 years), including 25 boys and one girl,
diagnosed in 1999-2003 in the Department of Haematology and
Paediatric Oncology, University of Medical Sciences in Poznañ.
The studied material was sampled before start of any therapy. In
12/22 examined sera of B-cell NHLs, IgG anti- EBV capsid anti-
gen (VCA) were positive; in one child both IgM and IgG anti-VCA
were positive. The histopathological diagnosis and selected clini-
cal data are presented in Table 1. The comparison group (non-neo-
plastic changes) included lymphoid organs (palatine tonsils, lymph
nodes, appendices) sampled from 8 boys and 3 girls (n=11; mean
age: 12±4 years) with no detectable signs/symptoms of EBV-relat-
ed diseases, in whom complete diagnostic efforts excluded neo-
plastic type of the lesions. Positive control included selected
organs (lymph nodes, liver, spleen, lungs, kidneys) sampled upon
autopsy of a 3-year-old child deceased due to acute diffuse primary
EBV infection (infectious mononucleosis syndrome). The studies
were conducted on serial, 5 μm paraffin sections, placed on the
SuperFrost/Plus microscopical slides. The archival material was
fixed in a buffered 10% formalin and embedded in paraffin using
the routine procedure. 
Immunocytochemical studies. Mouse anti-human monoclonal
antibodies were employed, directed against EBNA2 (1:50), LMP1
(1:50), BZLF1 (ZEBRA) (1:20), CD20 (1:20), CD45RO (1:2),
CD57 (1:100), CD68 and anti-human Von Willebrand Factor (both
ready for use dilutions) (all MAbs from DAKO, Glostrup, Den-
mark), CD3 (1:50), CD21 (1:100) and CD23 (ready to use)
(NOVOCASTRA Labs, Newcastle upon Tyne, UK). Then, the sec-
tions were treated with primary MAb at night at 4°C, then second-
ary biotinylated link anti-mouse and anti-rabbit IgG (DAKO) and
with the streptavidin-biotin-peroxidase complex (ABC) (DAKO).
The studies followed the classical ABC technique [22], associated
with the ImmunoMax technique [23] (for detecting CD21, CD23
and ZEBRA). In both techniques microwave-oven pretreatment for
antigen retrieval was used. In the ImmunoMax technique, the key
reaction involved 8 min incubation with biotinylated tyramine
(PerkinElmer life Sciences, Inc.) in dilution 1:50 at RT. This was
followed by another application of streptavidin complex. The
colour reaction was evoked with the HRP substrate, 0.05% 3,3-
diaminobenzidine tetrahydrochloride (DAB; DAKO) in 0.05 M
Tris-HCl buffer, pH=7.6, supplemented with 0.001% H2O2. In tis-
sue sections, endogenous peroxidase was blocked with 1% H2O2.
Control reactions employed control sera of the respective species
in 0.05 M Tris-HCl, pH=7.6, supplemented with 0.1% BSA and 15
mM sodium azide (negative control) (DAKO). 
Most of the histological preparations were subjected to double
immunocytochemical reactions, including lymphocyte B (CD20+),
T (CD3+, CD45RO+), NK-like cells (CD57+), macrophage mark-
er (CD68+) or marker of endothelial cells (Von Willebrand Factor)
and one of the EBV proteins. The terminal reaction product was
visualised using DAB (brownish-black signal) or Vector VIP sub-
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strate kit for peroxidase (Vector Labs, Burlingame, CA, USA)
(purple reaction product). Some preparations were counterstained
with hematoxylin and mounted, using a glycerol-based mounting
medium. Control reactions were based on substituting specific
antibodies with normal sera of the respective species in 0.05 M
Tris-HCl, pH=7.6, supplemented with 0.1% BSA and 15 mM sodi-
um azide (negative control).
In situ hybridization. For this purpose the fluorescein-conjugated
Epstein-Barr Virus Probe ISH Kit was used (NOVOCASTRA) for
demonstrating EBV-encoded small nuclear non-polyadenylated
RNAs (EBER1 and 2). The protocol of ISH reaction suggested by
NOVOCASTRA was used, with the earlier described modifica-
tions of our own [23]. The preliminary stages of the ISH protocol
were followed by incubation of paraffin sections with the probe for
2 h at the temperature of 37°C, then washed 3x3 min in TBS, con-
taining 0.1% Triton X-100. This was followed by 30 min incuba-
tion with blocking solution (normal rabbit serum diluted 1:5 with
TBS, containing 3% bovine albumin and 0.1% Triton X-100) at RT
and 30 min incubation with rabbit anti-FITC/AP diluted 1:100 with
TBS, 3% v/v BSA, 0.1% v/v Triton X-100. Subsequently, the sec-
tions were washed in TBS and in alkaline phosphatase substrate
buffer, pH=9.0, for 5 min. The next stage involved 14 to 16 h incu-
bation in the solution containing 5-bromo-4-chloro-3-indolylphos-
phate (BCIP) and nitro blue tetrazolium (NBT) in dimethylfor-
mamide solution, dissolved at the ratio of 1:50 in a buffer (100 mM
Tris/HCl, 100 mM NaCl, 50 Mm MgCl2). One μl levamisole
hydrochloride was added per each ml of the diluted enzyme sub-
strate. Terminal stage involved washing of the preparations in dis-
tilled water (2x5min) and mounting them in an aqueous balsam
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Table 1. Selected clinical data on children with B-cell non-Hodgkin's lymphomas.
Designations: BL - Burkitt's lymphoma; BLL- Burkitt's like lymphoma; DLL - diffuse large lymphoma; LL - lymphoblastic lymphoma; pos. - positive;
neg. -negative; VCA - EBV capsid antigen.
(DAKO). Positive control for the hybridocytochemical reaction
involved paraffin preparations of EBV infected organs from autop-
sy material and EBV-positive paraffin slides supplied by the pro-
ducer of the kit (NOVOCASTRA).
Isolation of DNA from paraffin sections and PCR technique.
Tissue fragments were extracted twice with xylene and were
washed twice in ethanol. After drying them, DNA was isolated
from the samples. For this purpose, DNA isolation buffer was pre-
pared, devoted to isolation of the acids from paraffin embedded tis-
sues. The buffer contained 50 mM Tris, pH 8.5; 1 mM EDTA;
0.5% Tween 20 and 200 μg/ml proteinase K. 200 μl of the buffer
was added to each sample. After 18 h incubation at 37°C the tubes
were centrifuged for 30 s, placed in 95°C for 8-10 min and cen-
trifuged again for 30 s. The tubes were stored at -20°C. PCR reac-
tion was performed using the following primers for the EBNA1
EBV gene fragment (Institute of Biochemistry and Biophysics
(IBB) PAN, Warszawa, Poland):
EB1: 5'-TGC GAG TAA TTG GTG ATG AG-3' (upstream)
EB2: 5'-TCG TCA GAC ATG ATT CAC AC-3' (downstream)
PCR reaction was performed in Eppendorf-type tubes, charged
consecutively with: 2.5 μl 10× amplification buffer [Tris-HCl,
KCl, (NH4)2SO4, 15 mM MgCl2 (Qiagen), pH=8.7; 0.5  l dNTP (10
mM; Qiagen)], 1 μl of each primer (0.5 μM; IBB), 5 μl DNA tem-
plate, 0.2 μl Taq DNA polymerase (2.5 U; Qiagen) and distilled
water to the final volume of 25 μl. In order to increase effective-
ness of amplification of the DNA isolated from paraffin embedded
tissues, the thermic profile of PCR reaction was modified and the
number of reaction cycles was increased. Tubes with the prepared
reaction mixture were placed in a thermocycler (DNA-Engine,
PTC-200, Peltier Thermal Cycler). After preliminary denaturation
at 94°C (3 min), 35 cycles were executed, each involving denatu-
ration at 94°C (30 s), annealing of primers at 56°C (30 s) and elon-
gation at 72°C (1 min). The second PCR was conducted in the
same conditions but 2 μl of the reactive mix following the first
PCR reaction was used as a template. Every time a negative con-
trol reaction was run, employing all the components required for
PCR reaction and water in place of DNA. The reaction product was
analysed immediately or after some time, storing it at the tempera-
ture of -20°C. In order to evaluate PCR, its products were subject-
ed to electrophoresis in 2% agarose gel in 1×TBE buffer (5×TBE:
Tris 54g, boric acid 27.5g, EDTA 0.5mM pH=8.0, water up to 1000
ml), with ethidium bromide supplementation (0.25 μg/ml), at 100-
120V. Every lane was charged with 15 μl sample plus 5 μl stain
(orange G). pUC19/Msp I (MBI Fermentas) was used as a sizing
marker of DNA fragments. Gels were viewed and photographed
under UV lamp. The amplified fragment originated from the region
of the EBNA1, it was 480 bp in length. 
Semiquantitative evaluation of the results and statistics. The
contents of EBV antigenic proteins, EBERs as well as of CD21 and
CD23 were calculated in B-cell NHLs and in non-neoplastic
lesions by two pathologist employing the semiquantitative IRS
scale, according to Remmele and Stegner [24] (Table 2), taking
into account intensity of the colour reaction and the number of pos-
itive cells. The final score represented a product of scores repre-
senting the two variables and ranged from 0 to 12 points. In every
preparation 10 visual fields were appraised at the magnification of
400× and mean scores were calculated. The means were compared
compared using the Mann-Whitney U test for non-parametric inde-
pendent data and the Wilcoxon test for non-parametric dependent
data. The exact Fisher's test was applied to compare manifestation
of DNA EBV in individual groups. Correlations between data rows
were determined employing Spearman's rank correlation index. 
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Table 2. Evaluation of EBNA1, LMP1, CD21, CD23 and EBERs
expression in studied preparation [according 24]. The final score
represents a product of the positive cells score (A) and the score
reflecting intensity of the colour reaction (B).
No reaction: score 0 points. Weak reaction: score 1 to 2 points. Average inten-
sity of the reaction: score 3 to 4 points. Intense reaction: score 6 to 12 points
Table 3. Semi-quantitative evaluation of selected markers of EBV
infection and of CD21/CD23 molecules in children with B-cell
non-Hodgkin's lymphomas using IRS scale [24].
Designation: nt - not tested
Results
Immunocytochemistry
EBNA2 and LMP1 proteins. Expression of EBNA2
protein was demonstrated in 12/26 examined patients
with B-cell NHLs (46%). Nuclear localisation of the
protein prevailed in individual, scattered neoplastic
cells (Fig. 1A). The cells involved mainly lymphocytes
of CD20+ phenotype. LMP1 protein was demonstrat-
ed in 19/26 studied B-cell NHLs (73%), in individual,
scattered cells or in their groups. Both cytoplasmic and
membraneous localisation of the protein was observed
(Fig. 1B). The reaction was most frequent in cells of
the CD20+ phenotype (Fig. 1C). Co-localisation of
CD3 or CD45RO and LMP1 protein was observed in
individual cases. Presence of the two viral proteins in
the same tumour occurred in 12/26 cases (Table 3). In
the group of patients more LMP1 could be demon-
strated as compared to EBNA2 and ZEBRA (p=0.01
and p=0.0001 respectively). The total frequency of
EBV-positive children amounted to 77% when pres-
ence of at least one tissue marker of EBV was taken as
indicating EBV positivity. In the non-neoplastic mate-
rial, expression of EBNA2 could not be demonstrated
in any of the patients while expression of LMP1 was
documented in 6/11 (54%) cases (Table 4). Expression
of LMP1 was significantly lower as compared to B-
cell NHLs (p=0.007) (Table 5). Co-expression of
LMP1 and CD20+ developed mainly in lymphocytes
in the enlarged lymphoid follicles of studied organs.
Among the children, 64% presented expression of at
least one EBV tissue marker. In the autopsy material of
the child deceased due to infectious mononucleosis
(positive control) markedly augmented expression of
the two latent proteins was noted in every of the stud-
ied organs (the data were not subjected to statistical
analysis). The proteins were detected in B lympho-
cytes (CD20+), cells of CD21+ phenotype (B lympho-
cytes, follicular dendritic cells) and individual T lym-
phocytes (CD3+ or CD45RO+), macrophages
(CD68+) and cells of CD57+ phenotype (Fig. 2A and
B). Numerous enlarged cells of CD20+ and CD68+
phenotype were noted, which manifested expression of
EBV proteins. 
BZLF1 (ZEBRA) protein. Cells immunopositive for
the protein were demonstrated in every organ of the
child with the diffuse form of EBV infectious mononu-
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Table 4. Semi-quantitative evaluation of selected markers of EBV infection and of CD21/CD23 molecules in children with non-neoplas-
tic lesions using IRS scale [24].
Table 5. Comparative immunocytochemical and hybridocyto-
chemical scoring of EBV proteins, EBERs, CD21 and CD23 in B-
cell NHLs vs non-neoplastic lesions in children. 
The Table lists mean values  ± SEM
Designations: NS - not significant; p - level of significance, *- p=0.01; **
- p=0.03 between EBNA2 i LMP1; *** - p=0.0001; p=0.03 between LMP1
and ZEBRA, respectively; 1p=0.06 and 2p=0.01 between CD21 and CD23.
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Fig. 1. Expression of EBV latent proteins in B-cell non-Hodgkin's lymphoma. A. Nuclear localisation of the EBNA2 in scattered cells.
B. Membranous and cytoplasmic localisation of LMP1 in a group of cells. C. Double-labelling immunocytochemistry reveals co-locali-
sation of LMP1 (brown staining) and CD20+ (purple staining) in individual tumour cells (arrow). ABC method. Nomarski optics (mag-
nification x400 (A, C), ×550 (B)). Fig. 2. Expression of EBV latent proteins in infectious mononucleosis (positive control). A. Double-
labelling immunocytochemistry reveals co-expression of LMP1 (purple staining) and CD20+ (brown staining) in a few cells (arrow),
while others express either LMP1 or CD20+. B. Double labelling immunohistochemistry for co-localisation of LMP1 (purple staining)
and CD21+ (brown staining) cells (arrow). ABC-double staining (magnification ×400). Fig. 3. Immunocytochemical localisation of CD21
in lymph nodule of a child with non-neoplastic lesions. ABC-Immunomax technique (magnification ×400).
cleosis and they were most numerous in the lungs and
lymph nodes. Cellular localisation of the protein
resembled that of latent proteins even if less
immunopositive cells were detected. In none of the B-
cell NHLs cases nor in the material with non-neoplas-
tic lesions could expression of BZLF1 protein be dis-
closed. 
CD21 and CD23 molecules. Expression of CD21 was
demonstrated in 11/25 (44%), and that of CD23 in
14/25 patients with B-cell NHLs (56%). CD23+ cells
were slightly more numerous as compared to CD21+
cells (p=0.06, borderline significance). In the material
with non-neoplastic lesions, CD21 was detected in
6/11 patients (54%), and CD23 in 10/11 patients (91%)
and in these cases CD23+ cells were significantly
more numerous than CD21+ cells (p=0.01). CD23+
cells were also significantly more numerous in the
group than in B-cell NHLs (p=0.05) (Table 5). Expres-
sion of both molecules in all studied tissues (lym-
phomas, non-neoplastic lesions and infectious
mononucleosis) manifested a membraneous pattern
and involved mainly lymphocytes within lymphoid
follicles (B lymphocytes, follicular dendritic cells)
(Fig. 3). 
In situ hybridization
Expression of Epstein-Barr virus small RNAs
(EBERs) was demonstrated in 12/25 patients with B-
cell NHLs (48%). Product of the hybrydocytochemical
reaction was noted in individual, scattered cells or
cells in small groups (Fig. 4A). In the material with
non-neoplastic lesions, expression of EBERs was
observed in 5/11 examined children (45%) in individ-
ual cells. No significant quantitative differences were
disclosed between expression of EBER in B-cell
NHLs and that in non-neoplastic cells. In the autopsy
material of the child with EBV infectious mononucle-
osis expression of EBERs was evident. It was most
intensely in lymph nodes and spleen (Fig. 4B). In pos-
itive control tissue material from the producer of the
kit (NOVOCASTRA), expression of EBERs was also
evident and was noted at the nuclei of EBV-infected
cells (Fig. 4C).
Polymerase chain reaction
A fragment of EBV genome (EBNA1) of 480 bp was
detected in 12/26 examined children with B-cell NHLs
(46%) (Table 3). Except of one case, the DNA was
detected in all the patients together with at least one
EBV protein and/or EBERs. Parallel expression of
EBERs, the two proteins and EBV DNA was docu-
mented in 6 cases of children with B-cell NHLs, who,
in parallel proved to be seropositive in five cases
(Table 2 and 3). In one child (case no 18) tissue detec-
tion of EBV infection was more sensitive than using
serological method. In the material of 8 patients (31%)
no DNA was detected even if expression of at least one
EBV protein and/or EBERs was detected. In the non-
neoplastic material EBV DNA was detected in 7/11
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Fig. 4. A. Hybridocytochemical reaction for EBV-RNAs (EBERs)
in a small group of B-cell NHLs. B. Intense hybridocytochemical
reaction for EBERs in EBV-positive lymph node of infectious
mononucleosis (positive control). C. Many EBERs-positive cells
of control material from the producer of the kit (magnification
×400). Hematoxylin counterstained (B).
studied patients (64%). In 6 of them LMP1 and/or
EBER were also detected by immunocytochemistry.
No significant differences in frequency of DNA EBV
detection were present between the group of children
with B-cell NHLs and the group with non-neoplastic
lesions (exact Fisher's test). PCR-amplified fragment
of 480 bp length (fragment of EBNA1 gene) from the
B-NHLs and controls is demonstrated on Fig. 5.
Correlations between cellular markers 
of EBV and CD21/CD23 molecules
In children with B-cell NHLs, positive correlation was
demonstrated between expression of  EBNA2 and
LMP1, EBNA2 and EBER as well as between LMP1
and EBER (Spearman correlation coefficient of 0.629;
0.489; 0.512, respectively, p<0.05). No correlation
could be disclosed between expression of cellular
EBV markers on one hand and those of CD21 and
CD23 on the other. Positive correlation was demon-
strated between expression of CD21 and CD23 (Spear-
man correlation coefficient of 0.485, p<0.01) in the
group of patients. In the material of non-neoplastic
lesions expression of LMP1 was positively correlated
with that of EBERs (Spearman correlation coefficient
of 0.834, p<0.05). Positive correlation was disclosed
between expression of CD21 and that of CD23 (Spear-
man correlation coefficient of 0.737, p<0.05). Also in
this group of patients no correlation could be disclosed
between expression of cellular EBV markers on one
hand and those of CD21 and CD23 on the other.
Latency pattern of EBV
Taking into account expression of the two latent phase
proteins (EBNA2 and LMP1) as well as expression of
EBERs, potential latency patterns were examined in
the studied children. The suggested latency patterns in
EBV positive patients are shown in Table 6. The eval-
uation did not include one child with B-cell NHLs, in
whom EBERs were not examined in tissue. The new
element involved demonstration of a novel latency
type, with negative EBERs, in 6/25 (24%) of the stud-
ied children with B-cell NHLs. Independently of
EBERs expression, in children with B-cell NHLs type
III of latency prevailed (11 patients). 
Correlations between cellular markers of EBV
and patient's age or histological diagnosis
Neither in the group of children with B-cell NHLs nor
in the group with non-neoplastic lesions could correla-
tion be observed between patient's age and examined
cellular markers of EBV. No significant relationships
could also be noted between specific histological diag-
noses and expression of EBV markers.
Discussion
Several data point to involvement of EBV as a co-fac-
tor in development of lymphoid and epithelial malig-
nancies, but the mechanisms involved remain unclear
[3,4,25,26]. In nonendemic regions of the world the
association of lymphoma with EBV is less stable and
can be noted in 20-80% cases [26]. 
EBNA1 and EBERs are the only EBV genes con-
sistently expressed in EBV positive Burkitt's lym-
phoma tumours [26,27], although some reports have
documented the expression of LMP1 and EBNA2 in
few tumour cells of some cases of endemic Burkitt's
lymphoma [28], and LMP1 in several cases of spo-
radic Burkitt's lymphoma [29]. Cellular localisation of
EBV proteins and/or EBV RNA (EBER) was
described mainly in lymphocytes B and plasma cells,
lymphocytes T, oral cavity and pharyngeal epithelium
as well as in tumours derived from the cell populations
[2,13,30].
Our present results have confirmed the expression
of EBNA2 and LMP1 in B-cell NHLs, mainly in cells
of the CD20+ phenotype (B lymphocytes) but also in
cells of CD21+ phenotype (B lymphocytes, follicular
dendritic cells) in individual cases. In the EBV infec-
tious mononucleosis patient expression of EBV pro-
teins involved an additional cell population
(CD45RO+, CD57+, CD68+). Expression of the pro-
tein of the lytic infection stage (ZEBRA) has been
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Table 6. Suggested latency patterns in EBV-positive cases of B-cell NHLs and non-neoplastic material (control). 
Designations: *- according Kuppers [13]. Numbers in brackets indicate percentage of patients with a given type of EBV latency per the total number of
patients in the studied group (e.g. B-cell NHLs n=25; non-neoplastic children n=11)
observed exclusively in the child with disseminated
form of infectious mononucleosis. Niedobitek et al.
showed ZEBRA (BZLF1) trans-activator protein
expression both in tissues of patients with infectious
mononucleosis and in a few tumor cells in 6 cases of
endemic Burkitt's lymphoma [28,30]. 
In our children with non-neoplastic lesions a sig-
nificantly lower expression of EBV proteins was
noted, as compared to children with B-cell NHLs and
in no other case expression of EBNA2 could be
demonstrated. Results of present study on expression
of all EBV markers in non-neoplastic lesions cannot be
related to literature data. Studies employing PCR tech-
niques and a newly developed genotyping technique
applied to saliva and peripheral blood are available,
which demonstrated both presence of EBV genome
and of specific sequences of LMP1 gene in 15-22%
healthy, immunocompetent individuals [31,32]. In a
variable proportion of cases (10 to over 80%) EBV
DNA has also been demonstrated in organs obtained
upon autopsy from patients with without apparent
EBV-related diseases. More numerous EBV-positive
cases have been detected in lymphoid organs [33],
which has been confirmed in present studies on detec-
tion of DNA in children with non-neoplastic lesions
(64%, lymphoid organs). 
In our study, differences have been noted in distri-
bution of the immunopositive cells in the patients. In
children with B-cell NHLs the cells with the protein
expression have tended to be scattered throughout the
tumour. In the non-neoplastic material, focal expres-
sion of LMP1 and EBER has been documented in nor-
mal or enlarged lymphoid follicles. No correlation
could have been disclosed between expression of EBV
tissue markers and a specific histological diagnosis. 
In order to define latency patterns in the studied
archival material, expression of the two latent proteins
(EBNA2, LMP1) and EBERs in tissue has been taken
into account. The obtained data have shown that
EBERs cannot be demonstrated in all cases with
expression of the latent proteins. The till now defined
EBV latency forms should include expression of
EBERs [13,34]. Six of our EBV positive children with
NHLs have manifested no expression of EBERs
despite the presence of other tissue markers of EBV
infection. Recently, however, a novel type of EBV
latency has been demonstrated, without expression of
the EBER genes in hepatocarcinoma tissue [35]. In our
previous study we documented an EBER-negative pat-
tern of EBV latency in children, as well as in adult
patients with B-cell NHLs [36]. In general, expression
of EBERs in present study has not significantly dif-
fered between children with B-cell NHLs and non-
neoplastic material. In the group of B-cell NHLs the
latency programme III have most frequently provided
the suggested forms of latency. The patterns are most
frequently encountered in Hodgkin's disease and in
primary effusion lymphoma [13,34]. Latency III is
also encountered in some post-transplant lymphopro-
liferative disorders and in lymphoblastoid cell lines
[28]. This type of latency, defined also as the growth
transcription programme, encompasses expression of
all the nine latent proteins and is responsible for the
capacity of EBV to transform normal, resting lympho-
cytes B in vitro to proliferating lymphoblasts. The pro-
gramme remains under control of the EBNA2 gene
[12]. In all, except one, of our children with the diag-
nosis of Burkitt's lymphoma tissue expression of EBV
has been accompanied by expression of at least one of
EBV proteins (EBNA2 and/or LMP1). This does not
confirm the general observations of other authors on
exclusive expression of EBNA1 and EBERs (latency
I) in endemic Burkitt's lymphomas [2,7,13]. The
expression of LMP1, in the absence of EBNA2, has
already been observed in EBV positive acquired
immunodeficiency syndrome (AIDS)-related BL
cases [29,34]. Even we did not test all of the known
viral proteins, we have provided potential EBV laten-
cy patterns in vivo in children with nonendemic
forms of BL. In our tissue material the latency pat-
terns have proven to be more complex than indicated
by histological diagnoses and the till now published
reports. In paediatric cases of Burkitt's lymphoma we
have confirmed the numerous reports of other authors
on the potential for a phenotypic drift from latency I
to latency III, which has been observed previously in
some BL cell lines and that a similar phenomenon
may occur in Burkitt lymphoma in vivo [28]. Our
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Fig. 5. Electrophoresis in 2% agarose of PCR-amplified EBV-
DNA fragment of 480 bp length (EBNA1) from the tumour of B-
cell NHL and controls. Legend: 1 - pUC 19 DNA/Msp I (Hpa II)
size marker; 2 - PCR-amplified product of EBV-DNA (EBNA1)
(480 bp) using oligonucleotide primers EB1 and EB2 in positive
control material; 3 - EBV- negative lymphoma; no product in PCR
reaction; 4 - PCR-amplified product of EBV-DNA (EBNA1) (480
bp) in B-cell NHL (sample no 26749-5); 5 - PCR-amplified prod-
uct of EBV-DNA (EBNA1) (480 bp) in EBV positive appendix
(sample no 28907).
studies have demonstrated expression of various phe-
notypes of the two EBV latent proteins in a propor-
tion of cells in B-cell NHL tumors in children and
may supplement the till now described EBV latency
forms in nonendemic areas. In the tissue material
with the non-neoplastic lesions the type II latency
prevailed, with expression of EBERs as well as of
LMP2 protein. In the patients EBV DNA has also
been demonstrated. 
Several literature references back up the hypothesis
that EBNA2 represents the principal inducer of LMP1
and LMP2 expression [2,7], even if also an in vitro evi-
dence is available on the absence of correlation
between expressions of the two proteins [37]. 
Our present results have demonstrated positive cor-
relations between expression of EBNA2 and LMP1 as
well as between that of the two proteins and EBERs in
children with B-cell NHLs. Both EBNA2 and LMP1
are known to activate primary B lymphocytes and par-
ticipate in their transformation, inducing expression
of, i.e., CD21 and CD23 genes [2,8,14,17]. The in vitro
studies indicate that expression of CD21 is related to
the stage of cell cycle and is more pronounced at the
G1 phase. Higher amounts of CD21 have been
observed in the more differentiated cells of human cell
line of B lymphocytes [18]. 
In our studies no quantitative differences could
have been noted in expression of CD21 between
patients with B-cell NHLs as compared to the group
with reactive stimulation of lymphoid system. Positive
correlations involved reciprocal expression of CD21
and CD23 in B-cell NHLs children and non-neoplastic
material. In both group of patients significantly more
CD23 than CD21 has been detected. On the other
hand, we have been unable to confirm the positive cor-
relation between expression of EBV tissue markers
and that of CD21/CD23 in B-cell NHLs and therefore,
in our tumour patients, EBV has shown no significant
effect on increased expression of the molecules. In the
case of CD23 expression, which has been significant-
ly lower in B-cell NHLs as compared to children with
non-neoplastic lesions, this might be possibly
explained by the modulating effect of EBNA2 (present
only in B-cell NHLs) on expression of CD23. In the in
vitro studies, EBNA2 protein decreased expression of
CD23 on cell membranes, resulting in augmented level
of CD23 steady-state RNA coding for the form A of
the protein, which is not detectable at the cell surface
but directly secreted [19]. 
We are unable to confirm the in vitro observations,
indicating induction of CD21 and CD23 gene expres-
sion in primary B lymphocytes by EBV infection
[8,14]. Involvement of EBNA2 and LMP1 in transfor-
mation of B lymphocytes in the form of in vivo activa-
tion of CD21 and CD23 molecules is probably of a
more complex nature and may be related to the stage
of lymphocyte differentiation, as suggested by some
authors of in vitro experiments [18]. 
Summing up, it should be stressed that studies
employing various techniques of molecular biology
have permitted for a more complete appraisal of the
actual EBV expression in B-cell lymphomas, defini-
tion of the new latency forms of the virus and for pre-
cise detecting of EBV replication sites in the cells. The
total detectability of EBV tissue markers both in B-
cells NHLs (77%), and in the group of non-neoplastic
lesions (64%) in our patients suggests that the notion
of EBV infection representing a sufficient proof for the
oncogenic action of EBV should be treated as highly
equivocal. The definitely more pronounced cellular
expression of latent tissue markers of EBV in B-cell
NHLs children as compared to the non-neoplastic
material may point to a potential role of EBV in patho-
genesis of lymphoma in this group of population. Iso-
lated detection of EBV DNA in tissue material should
be treated with caution as a pathogenetic index if no
EBV clonality tests have been performed. Other
authors have also pointed to high proportion of EBV-
positive persons who manifest no clinical signs/symp-
toms of EBV-related diseases [31, 33]. Except of EBV,
recently various other potential co-factors are dis-
cussed of the endemic development of Burkitt's lym-
phoma, such as malaria, arboviruses and extracts of a
commonly used plant, Euphorbia tirucalli [38]. Dis-
closure of such co-factors active in our geographic
zone will involve further investigations and on a larg-
er group of patients. 
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